Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Dise...
Prothena Corporation plc - Ordinary Shares (PRTA)
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.prothena.com
Company Research
Source: Business Wire
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of diseaseFast Track Designation recognizes the potential of anti-MTBR tau to be an important treatment option for patients with Alzheimer’s disease DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), announced today that Bristol Myers Squibb communicated in a press release that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BMS-986446, a potential best-in-class anti-microtubule binding region-tau (anti-MTBR-tau) antibody currently in Phase 2 development for the treatment of early Alzheimer’s disease. Fast Track Designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and fill an unmet medical need.Alzheimer’s disease — the most common type of dementia in adults — is a progressive, multifaceted and devastating neurodegenerative
Show less
Read more
Impact Snapshot
Event Time:
PRTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRTA alerts
High impacting Prothena Corporation plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRTA
News
- Prothena (NASDAQ:PRTA) had its price target raised by analysts at Citizens Jmp from $11.00 to $19.00. They now have a "market outperform" rating on the stock.MarketBeat
- Prothena (NASDAQ:PRTA) was given a new $19.00 price target on by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Prothena (NASDAQ:PRTA) was given a new $19.00 price target on by analysts at JMP Securities.MarketBeat
- Prothena (NASDAQ:PRTA) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- Why The Narrative Around Prothena Is Shifting After Analysts Raise Targets and Clinical Updates [Yahoo! Finance]Yahoo! Finance
PRTA
Earnings
- 11/6/25 - Miss
PRTA
Sec Filings
- 11/19/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- PRTA's page on the SEC website